Your pharmacist can provide more information about human antihemophilic factor.

Your body may develop antibodies to antihemophilic factor, making it less effective.

Human antihemophilic factor is usually given every 8 to 24 hours for 1 to 4 days, depending on the reason you are using the medication.

There may be other drugs not listed that can affect human antihemophilic factor.

Human antihemophilic factor is sometimes used only as needed, so you may not be on a dosing schedule.

Human antihemophilic factor is not for use in people with von Willebrand disease.

Human antihemophilic factor may also be used for other purposes not listed in this medication guide.

Human antihemophilic factor is given as an injection through a needle placed into a vein.

Do not use this medication if you have ever had a severe allergic reaction to antihemophilic factor in the past.

An overdose of human antihemophilic factor is not expected to produce life-threatening symptoms.

Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using human antihemophilic factor.

Human antihemophilic factor will not treat von Willebrand disease.

Human antihemophilic factor must be mixed with a liquid (diluent) before injecting it.

Your doctor may want you to receive a hepatitis vaccination before you start using human antihemophilic factor.

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.

It is not known whether human antihemophilic factor passes into breast milk or if it could harm a nursing baby.

His team developed a concentrate of the antihemophilic factor, AHF, that provided an effective treatment.

Human antihemophilic factor is made from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease.

This product contains a man-made form of factor VIII, also called antihemophilic factor.

A lack of antihemophilic factor VIII is the cause of hemophilia A.

Before using human antihemophilic factor, your specific blood clotting disorder must be diagnosed as factor VIII deficiency.

Brinkhous made the seminal discovery of antihemophilic factor (Factor VIII) and showed that it was lacking in hemophiliac patients.

In medicine genetic engineering has been used to mass-produce insulin, human growth hormones, follistim (for treating infertility), human albumin, monoclonal antibodies, antihemophilic factors, vaccines and many other drugs.

Moroctocog alfa is a glycoprotein (trade name ReFacto) and a recombinant Antihemophilic Factor genetically engineered from Chinese hamster ovary (CHO) cell line.

Human antihemophilic factor is used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia.

Similarly the New World Junin virus causes Argentine hemorrhagic fever.

This virus causes Argentine hemorrhagic fever in a limited agricultural area of the pampas in Argentina.

Viral infections: Arenaviruses causing Argentine hemorrhagic fever or Bolivian Hemorrhagic Fever among others.

A member of the genus Arenavirus, Junin virus characteristically causes Argentine hemorrhagic fever (AHF).

Later still, one of Dr. Peters's colleagues injected himself with Junin virus (which causes Argentine hemorrhagic fever) just to prove that he'd really isolated the pathogen.

Investigational vaccines exist for Argentine hemorrhagic fever and RVF; however, neither is approved by FDA or commonly available in the United States.

Returning to Argentina, he began research on Argentine hemorrhagic fever, a condition known among the country's rural population as the mal de los rastrojos ("the sickness of the corn straw").

For example, Dr. Chomel said, the corn mouse that carries the virus that causes Argentine hemorrhagic fever has spread its range with changes in farming, leading to outbreaks of the bleeding disease.

The United States Army and the Argentine Government are inoculating part of this group with a vaccine developed at Fort Detrick against Junin virus, a disease also called Argentine hemorrhagic fever.

Argentine hemorrhagic fever was one of three hemorrhagic fevers and one of more than a dozen agents that the United States researched as potential biological weapons before the nation suspended its biological weapons program.

Argentine hemorrhagic fever (AHF) or O'Higgins disease, also known in Argentina as mal de los rastrojos, stubble disease, is a hemorrhagic fever and zoonotic infectious disease occurring in Argentina.

Although, there are no cures or immunization for the disease, a vaccine developed for the genetically related Junín virus which causes Argentine hemorrhagic fever has shown evidence of cross-reactivity to Machupo virus and may therefore be an effective prophylactic measure for people at high risk of infection.

The city, a prosperous agricultural hub in the heart of Argentina's corn belt, was also the epicenter in 1958 of a sudden outbreak of Argentine hemorrhagic fever, a condition known among the country's rural population as the mal de los rastrojos ("the sickness of the corn straw").